EP2699109A1 - Compositions probiotiques d'hydrate de carbone - Google Patents

Compositions probiotiques d'hydrate de carbone

Info

Publication number
EP2699109A1
EP2699109A1 EP12710451.1A EP12710451A EP2699109A1 EP 2699109 A1 EP2699109 A1 EP 2699109A1 EP 12710451 A EP12710451 A EP 12710451A EP 2699109 A1 EP2699109 A1 EP 2699109A1
Authority
EP
European Patent Office
Prior art keywords
composition
composition according
resistant
vitamin
glucans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12710451.1A
Other languages
German (de)
English (en)
Inventor
Günther Sawatzki
Richard ZELENKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Milchkontor eG
Original Assignee
Deutsches Milchkontor eG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Milchkontor eG filed Critical Deutsches Milchkontor eG
Publication of EP2699109A1 publication Critical patent/EP2699109A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to carbohydrate compositions containing galacto-oligosaccharides and glucans having basic structures of al-4 and / or al-6-linked glucose units used in the preparation of prebiotic-type foods or pharmaceuticals.
  • Carbohydrates are used primarily to supply energy to the host organism.
  • scientific research has shown that some carbohydrates perform additional functions that support certain biological processes. These substances are also used as basic substances for functional foods.
  • foods and pharmaceuticals are increasingly being added to carbohydrates (so-called prebiotics) which have a prebiotic effect.
  • prebiotics is understood as influencing the bacterial colonization, in particular of the large intestine.
  • Prebiotics are characterized by the fact that they are not digested in the small intestine and thus reach the colon unabsorbed, where they are selectively digested by some bacteria and serve their diet.
  • prebiotic substances specifically support only those microorganisms which have beneficial effects on the host organism.
  • the intestinal flora is composed of several 1 00 bacterial species, the majority of which is present in the colon. At the same time, one only knows a selection of bacteria that can be detected outside the intestine. With modern DNA-based methods such. With metagenome analysis, one also tries to detect those bacteria about which so far very little is known. Nevertheless, classical bacteriological methods are still mainly used to detect the growth of bacteria and the suppression of pathogenic bacteria from stool sources in the laboratory.
  • Some prebiotic substances belonging to carbohydrates are primarily metabolized by so-called bifidobacteria and lactic acid bacteria (such as Lactobacillus acidophilus) in the colon.
  • these bacteria especially the bifidobacteria, selectively grow stronger than the other bacteria and in part suppress the growth of other bacteria, especially pathogenic bacteria. This is called a bifidogenic effect.
  • positive health effects such as the suppression of diseases, a better prosperity etc. on the host organism are discussed.
  • anti-pathogenic effects of prebiotics include a shorter duration of food in the intestine, a lowering of the cholesterol level, a less high glycemic response, an improvement in bone health (calcium absorption), one decreased energy intake, an improvement in the symptoms of chronic intestinal inflammation and a reduction in the risk of a disease of the intestinal cancer s.
  • glucans having a basic structure of glucose units connected to a 1 -4 and / or a 1-6 can be combined much better with galactooligosaccharides for a prebiotic composition.
  • the present invention therefore provides the use of a carbohydrate composition containing at least one galactooligosaccharide and at least one glucan having a basic structure of glucose units linked to al-4 and / or al-6 for the production of an agent having a prebiotic effect.
  • this glucan is a water-soluble glucan.
  • soluble carbohydrates are carbohydrates which form a homogeneous solution in the physical sense in water in a concentration of at least 1 g / L at room temperature (see Rompps Chemie Lexikon).
  • Prebiotic carbohydrates or prebiotics according to the invention and according to the internationally accepted definition indigestible, ie non-absorbable from the small intestine of healthy humans food ingredients that selectively stimulate the growth and / or activity of a bacterial species or a limited number of bacterial species and thus a health-promoting effect on the host organism (Roberfroid, MC; Prebiotics: prefential substrates for specific germs), at J Clin Nutr 73 (suppl): 406S-409S (2001)).
  • the invention is characterized in that in the combined use of galactooligosaccharides with glucans having a basic structure of al-4 and / or al-6 linked glucose units, a marked synergistic prebiotic effect occurs.
  • the glucans used according to the invention are oligosaccharides and / or polysaccharides having at least 3 D-glucose monomers which are linked to one another by a glycosidic bond, in this case by an .alpha.-glycosidic bond. These may each be contained singly or in a mixture of two or more glucans in the carbohydrate composition.
  • glucans are dextrans (al, 6-glucan + Glc branching (a-1,4 / 1,2 / 1,3)), mutans (a-1,6-glucan), glycogens (a-1,4- and ⁇ -1,6-glucan), pullulans ( ⁇ -1,4 and ⁇ , 6-glucan) and starches ( ⁇ -1,4 and ⁇ , 6-glucan (amylose, amylopectin)).
  • carbohydrate compositions contain starches.
  • the glucans used according to the invention are resistant starches, which in the Degradation of the resistant starches resulting degradation products and / or resistant Polydextrosen.
  • Resistant starches most preferably used are resistant maltodextrins and / or resistant dextrins.
  • Resistant starches are understood to mean substances formed chemically, like ordinary starches, and those resulting from the degradation of starch, which are normally not digestible, that is, which are not degradable by human digestive enzymes.
  • the resistant starches are therefore starches and starch-forming products that are not sorbed by the small intestine of healthy people and therefore belong to the fiber.
  • the resistant starches can be divided into four subspecies:
  • Type 1 physically inaccessible starches (for example, grains and plant components)
  • Type 2 native, granular starch with high crystallinity (for example from bananas)
  • Type 3 partially highly crystalline starches (boiled) generated by retrogradation (gelatinization)
  • Type 4 Chemically modified starches Of these so-called dietary fibers, positive effects are discussed by the corresponding bacteria, in particular by the formation of short-chain fatty acids as major end products of metabolism in the large intestine. These are the metabolites acetate, propionate and butyrate (D .L. Topping and P.M. Clifton; Short-chain fatty acids and human colonic function: Roles of resistant starch and non-starch polysaccharides; Physiol. Rev. 8 1: 103 1 - 1064 (2001)).
  • butyrate has beneficial effects on intestinal functions, in particular on the development of intestinal cells, by being used predominantly as an energy substrate of the host organism.
  • resistant starches The production of resistant starches is described, inter alia, for example in WO 2008/080630. This publication also contains further information on the molecular structure of resistant starches, on determination methods and on the sole use as a prebiotic dietary ingredient.
  • water-soluble maltodextrins are also available on the market. These include, for example, the products Nutrio se-FB and Nutriose-FM (from Roquette, with a degree of polymerization DP of approx.> 10) and the product Fibersol-2 (from ADM / Matsutani), without restricting the general.
  • water-soluble resitent dextrins / polydextroses are now available on the market. These include the products Litesse, Litesse-Two and Litesse-Ultra (by Danisco) and the product STA-LITE (by Töre & Lyle) (all with a DP degree of about> 12).
  • modified resistant starches to improve the microbial colonization of the digestive tract has been described for example in EP 0 910 359.
  • the prebiotic effect of resistant starch alone is well known.
  • a combination of carbohydrates using resistant starch as a prebiotic combined product is also described, for example, in WO 2005/056023.
  • the particularly effective prebiotic effect using the combination of galactooligosaccharides and resistant starches according to the invention has not been described anywhere.
  • the carbohydrate composition according to the invention contains no fructooligosaccharides.
  • the polydextroses are likely to specifically stimulate the bifidobacteria but not the lactobacilli (HM Probert, JHA Apaj alahti, N. Rautonen, J. Stowell, and GR Gibson; polydextrose, lactitol, and fructo-oligosaccharide fermentation by colonic bacteria in a three-stage continuous culture system; Appl.Environ.Microbiol. 70: 4505 - 45 1 1 (2004)) and selectively suppress bacteroid species.
  • lactobacilli HM Probert, JHA Apaj alahti, N. Rautonen, J. Stowell, and GR Gibson
  • polydextrose, lactitol, and fructo-oligosaccharide fermentation by colonic bacteria in a three-stage continuous culture system Appl.Environ.Microbiol. 70: 4505 - 45 1 1 (2004)
  • the galactooligosaccharides according to the invention are water-soluble, oligosaccharide carbohydrates having 3 to 9 monosaccharide units, preferably having 3 to 6 monosaccharide units, the monosaccharide being mainly galactose, in particular D-galactose.
  • the galactooligosaccharides are therefore preferably tri-tetra-, penta- or hexaoligosaccharides.
  • ⁇ -galacto-oligosaccharides may each be contained singly or in a mixture of two or more galactooligosaccharides in the carbohydrate composition. It is particularly preferred to use ⁇ -galacto-oligosaccharides or ⁇ -galacto-oligosaccharides. Very particular preference is given to using ⁇ -galactooligosaccharides.
  • Galacto-oligosaccharides are industrially produced using the enzyme beta-galactosidase by the so-called transglycosylation reaction. Therefore, they are also often referred to as transgalactooligosaccharides (TO S, TGO S).
  • galactooligosaccharides according to the invention are the commercially available products Oligomate (Yakult) and Vivinal-GO S (DOMO / Frieslandfoods).
  • Preferred mixtures for the prebiotic carbohydrate composition according to the invention contain 50-95% by weight of galactooligosaccharides and 5-50% by weight of .gtoreq.-4 and / or .alpha.-6 linked glucans.
  • Particularly preferred is a composition of 80-90% by weight of galactooligosac and 20-10% by weight of glucans with glucose units connected from od -4 and / or al -6.
  • Modified monomers can also be used for the carbohydrates used according to the invention. For example, it is possible to carry out enzymatic modification of galactooligosaccharides or glucans. Alternatively, it is also possible to make a technical modification. Further, the monomers or units constructed therefrom may also be modified by -O SO 3 H and / or -OPO 3 H groups.
  • a composition according to the invention consisting of 80% by weight galactooligosaccharides (Vivinal-GO S, DOMO / Frieslandfoods) and 20% by weight resistant maltodextrins (Nutriose-FM, Roquette) was compared to 100% galactooligosaccharides or 100% resistant Maltodextrins were tested as part of an infant formula at a concentration of 4g per liter in 240 infants aged 6-8 months in a clinical trial.
  • the clinical trial revealed that the composition of the present invention, the combination of galacto-oligosaccharides and resistant maltodextrins, had significantly more pronounced effects on the bacterial composition in the infant's stool compared to the same amount of each carbohydrate in the infant formula. Even with a doubling of the quantities In each case, the effect of the composition according to the invention could not be achieved.
  • compositions of the invention may be included in the following products: infant formulas for premature infants and normal-weight infants, infant and pediatric infants, clinical foods, pharmaceuticals, and dietetic foods.
  • the composition of the invention can make up a part of these products or replace conventional components.
  • existing carbohydrates can be partially replaced or supplemented by the composition.
  • lactose lactose
  • lactose lactose
  • the amount of the composition used according to the invention is adjusted according to age to specific daily amounts and the dosage form used.
  • infant formula and infant formula for infants between 3 and 20 g of the composition of the invention per day are presented.
  • Ratios may contain between 2-50 g of the composition of the invention per daily ration. This may be present as a component in both foods, dietetic foods, nutritional supplements, clinical foods and pharmaceuticals.
  • the compositions according to the invention can also be provided in combination with other constituents, both liquid, solid, as a powder, as a spray-dried powder, as emulsions, as compressed tablets or in the form of capsules.
  • composition according to the invention for various products is described below with reference to corresponding example formulations (all powder products) in detail.
  • advertising for the exemplary diets the indivi- dual ingredient lists and the ingredients listed as tables.
  • ingredients are prepared according to techniques well known to those skilled in the art, such as by mixing in the aqueous phase, homogenizing, pasteurizing, spray-drying and optionally dry-blending with the additional possibility of agglomerating the powders.
  • Baby milk formula The formula given is the basis for a so-called starter diet, ie for a baby born normal from birth
  • Skimmed milk 1 85 g demineralized whey powder 46, 7 g vegetable oils (contains soya ale-plant
  • Vitamin A vitamins 695 ⁇ g
  • the recipe given is the basis for a so-called follow-on milk 2, that is, for a diet that can be administered to normal-born infants after the 6th month.
  • Emulsifier soya lecithin 655 mg
  • Vitamin B12 0.54 ⁇
  • Vitamin B12 ⁇ g 1.50 0.21
  • a medicinal food is a food for sick infants, children and adults suffering from intestinal disorders (e.g., diarrhea).
  • the following recipe is given for such a healing diet, liquid form can be administered.
  • Vitamin D3 8.5 ⁇ g
  • Vitamin B12 0.49 ⁇ g

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une utilisation d'une composition d'hydrate de carbone pour la production d'un agent ayant une action probiotique, la composition contenant en tant qu'hydrates de carbone en plus de mono- et/ou disaccharides au moins un galactooligosaccharide et au moins un glucane ayant une structure de base à partir de motifs glucose reliés en α 1 -4 et/ou en α 1 -6.
EP12710451.1A 2011-02-25 2012-02-14 Compositions probiotiques d'hydrate de carbone Withdrawn EP2699109A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011012494A DE102011012494A1 (de) 2011-02-25 2011-02-25 Prebiotische Kohlenhydrat-Zusammensetzungen
PCT/EP2012/052474 WO2012113677A1 (fr) 2011-02-25 2012-02-14 Compositions probiotiques d'hydrate de carbone

Publications (1)

Publication Number Publication Date
EP2699109A1 true EP2699109A1 (fr) 2014-02-26

Family

ID=45878904

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12710451.1A Withdrawn EP2699109A1 (fr) 2011-02-25 2012-02-14 Compositions probiotiques d'hydrate de carbone

Country Status (6)

Country Link
EP (1) EP2699109A1 (fr)
CN (1) CN103533851A (fr)
DE (1) DE102011012494A1 (fr)
EA (1) EA201391205A1 (fr)
UA (1) UA109930C2 (fr)
WO (1) WO2012113677A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103609748A (zh) * 2013-12-10 2014-03-05 内蒙古伊利实业集团股份有限公司 一种降血糖孕妇奶粉及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN880996A0 (en) 1996-03-20 1996-04-18 Arnott's Biscuits Limited Selection and/or enhancement of resident microorganisms in the gastrointestinal tract
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
NO320546B1 (no) 2003-12-12 2005-12-19 Nova Biotics As Prebiotiske kombinasjonsprodukter
EP1817964A1 (fr) * 2006-02-13 2007-08-15 Sweetwell NV Remplacement fonctionnel de sucre
HUP0500582A1 (hu) 2005-06-13 2007-08-28 Csaba Jozsef Dr Jaszberenyi Szinergetikus élettani hatású élelmiszerek, élelmiszer-adalékok és táplálék-kiegészítõk vagy takarmányadalékok
US8075934B2 (en) * 2008-10-24 2011-12-13 Mead Johnson Nutrition Company Nutritional composition with improved digestibility
US9247763B2 (en) * 2005-07-05 2016-02-02 N.V. Nutricia Carbohydrate fraction and use thereof for a flat postprandial glucose response
US20070218170A1 (en) * 2006-03-03 2007-09-20 Health Beverage Llc Fiber Containing Alkaline Beverage and Methods For Production Thereof
CA2645472C (fr) * 2006-03-10 2015-09-15 N.V. Nutricia Utilisation de saccharides non digestibles pour assurer a un nouveau-ne le meilleur depart dans la vie
WO2008054193A1 (fr) * 2006-11-02 2008-05-08 N.V. Nutricia Produits alimentaires contenant des oligomères à base de saccharide
AR064557A1 (es) 2006-12-29 2009-04-08 Bayer Cropscience Ag Almidon de maiz y harinas y alimentos de maiz que comprenden este almidon de maiz
US20090118227A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods
WO2009075564A1 (fr) * 2007-12-10 2009-06-18 N.V. Nutricia Mélange de fibres pédiatriques
US8425955B2 (en) * 2009-02-12 2013-04-23 Mead Johnson Nutrition Company Nutritional composition with prebiotic component
US8293264B2 (en) * 2009-05-11 2012-10-23 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth

Also Published As

Publication number Publication date
EA201391205A1 (ru) 2014-02-28
UA109930C2 (uk) 2015-10-26
CN103533851A (zh) 2014-01-22
DE102011012494A1 (de) 2012-08-30
WO2012113677A1 (fr) 2012-08-30

Similar Documents

Publication Publication Date Title
DE60128395T2 (de) Ernährungszusammensetzung mit gesundheitsfördernder wirkung enthaltend oligosaccharide
EP1105002B1 (fr) Melanges d'hydrates de carbone
DE60204058T2 (de) Netzwerk-bildende und pektin-enthaltende zubereitung
EP1267891B1 (fr) Glucides antiadhesifs
DE60215156T3 (de) Säurereguliertes viskoses ballaststoffsystem und seine verwendung
EP0957692B1 (fr) Melange d'hydrates de carbone
CA2991450C (fr) Utilisation de la polydextrose pour simuler les caracteristiques fonctionnelles des oligosaccharides du lait maternel, pour des bebes allaites artificiellement
DE60221234T2 (de) Verwendung von füllstoffe als sättigungsmittel
EP2230943B1 (fr) Mélange nutritionnel à base de fibres pour patients pédiatriques
DE202016008919U1 (de) Zusammensetzungen zur Verwendung bei der Prävention oder Behandlung von gastrointestinalen Infektionen/Entzündungen bei Säuglingen oder Kleinkindern
CN101945589A (zh) 用于改善肠道微生物群的非消化性碳水化合物的用途
DE60309169T2 (de) Verwendung vom pullulan als langsam verdauliches kohlenhydrat
TW201233334A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
DE60022513T2 (de) Verwendung eines fettsäure derivates in nasale gastrale enterale formulierungen
DE60217431T2 (de) Faserhaltiges Präparat zur enteralen Ernährung
WO2012113677A1 (fr) Compositions probiotiques d'hydrate de carbone
KR20070049376A (ko) 다이어트 음료 조성물
CN117715540A (zh) 用于喂养接受婴儿配方和人母乳的婴儿的婴儿配方
WO2023205762A1 (fr) Procédés et compositions pour ralentir le développement du diabète ou réduire un risque de diabète
TW201244721A (en) Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
DE19861508A1 (de) Kohlenhydratmischung
DE102006001017A1 (de) Mittel zur Anwendung bei Blutzuckerstoffwechselstörungen einschließlich Diabetes
DE102005061329A1 (de) Mittel zur Anwendung bei Blutzuckerstoffwechselstörungen einschließlich Diabetes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1193548

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160901

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1193548

Country of ref document: HK